ONA Therapeutics

ONA Therapeutics is a biotechnology company that develops innovative antibody-drug conjugates (ADCs) and monoclonal antibodies aimed at treating advanced cancers, especially those that are resistant to treatment. Founded in 2019 as a spin-off from ICREA and IRB Barcelona, the company is headquartered in the Barcelona Science Park and operates with a small, experienced team.

The company focuses on discovering new therapeutic targets from the biology of treatment-refractory cancer patients. Its lead program, ONA-255, is a first-in-class ADC targeting refractory breast cancer and other solid tumors, with clinical trials expected to start by the end of 2025. Another program, ONA-389, targets advanced microsatellite stable colon and liver cancers, with studies set to begin in late 2025. Additionally, ONA Therapeutics is developing a monoclonal antibody against CD36, which plays a role in cancer progression. The company has received recognition for its promising work in the biotechnology field.